Healthpeak Properties stock: recent performance snapshot

Healthpeak Properties (DOC) has drawn investor attention after recent trading, with the stock last closing at $20.47 and showing a mix of short term and longer term total returns that highlight its healthcare focused real estate footprint.

While the latest 1 day share price move was slightly lower, the stock has a 7 day share price return of 7.34% and a 90 day share price return of 21.12%, alongside a 1 year total shareholder return of 25.32%. This points to improving momentum compared with the 5 year total shareholder return that remains down 21.42%.

If Healthpeak’s recent move has you thinking about where else capital might work harder, this could be a good moment to scan 34 power grid technology and infrastructure stocks

With Healthpeak trading close to some analysts’ targets yet also showing a sizeable model based intrinsic discount, the key question is whether the stock still offers a meaningful entry point or if the market is already pricing in future growth.

Most Popular Narrative: 1.7% Undervalued

With Healthpeak Properties last closing at $20.47 and the most followed fair value estimate at $20.83, the narrative frames a small discount and leans heavily on long term demand for healthcare focused real estate.

The accelerating shift of surgical and specialty care from inpatient hospital settings to outpatient centers, supported by anticipated regulatory changes (CMS inpatient only default reversal), is set to drive sustained tenant demand and pricing power for Healthpeak's modern, high acuity outpatient medical buildings, which should translate into increased occupancy rates and same store NOI growth.

Curious what has to happen for this valuation to hold up? The narrative leans on steady revenue, thinner margins, and a future earnings multiple that stands out. The full write up spells out the growth, profitability and discount rate mix that supports a fair value close to today’s price without assuming rapid expansion.

Result: Fair Value of $20.83 (UNDERVALUED)

However, this hinges on lab and outpatient tenants staying healthy. At the same time, concentrated exposure to a few key markets leaves the stock sensitive to local oversupply or funding stress.

Another view on valuation: earnings multiple sends a different signal

The SWS DCF model suggests Healthpeak Properties is trading at a large discount, with the stock at $20.47 versus an estimated future cash flow value of $34.55, which points to undervaluation if those cash flow assumptions hold.

Set against that, the current P/E of 63.7x screens as expensive compared with a fair ratio of 29.3x, the US Health Care REITs industry at 38.7x, and global peers at 20.8x. In other words, you are paying a rich earnings multiple for a stock the cash flow model argues is cheap. Which signal do you trust more for your own thesis?

Next Steps

Mixed signals on value and sentiment can be confusing, so do not leave your view half formed. Review the data, weigh the trade offs and check the 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If this valuation puzzle has sharpened your thinking, keep that momentum going by lining up fresh, data backed stock ideas tailored to different goals.

• Target potential mispricings by scanning companies that screen as high quality and out of favor using the 47 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses that show strong finances and fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by searching for underfollowed companies with solid profiles in the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.